Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) was upgraded by equities research analysts at StockNews.com to a "sell" rating in a research report issued to clients and investors on Friday.
Several other research firms have also commented on NTLA. Evercore ISI raised Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Wedbush reissued a "neutral" rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Thursday. The Goldman Sachs Group cut their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus decreased their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating for the company in a research report on Wednesday, September 11th. Finally, Barclays lowered their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating for the company in a research note on Friday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $57.94.
Get Our Latest Stock Analysis on NTLA
Intellia Therapeutics Stock Performance
Intellia Therapeutics stock traded up $0.73 during trading hours on Friday, hitting $16.73. The company had a trading volume of 2,417,141 shares, compared to its average volume of 2,854,846. The firm has a market cap of $1.70 billion, a P/E ratio of -3.05 and a beta of 1.81. Intellia Therapeutics has a 1 year low of $13.95 and a 1 year high of $34.87. The company has a 50-day moving average price of $19.17 and a two-hundred day moving average price of $22.22.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts' expectations of $8.28 million. During the same period in the previous year, the company posted ($1.38) EPS. Intellia Therapeutics's revenue for the quarter was down 24.1% on a year-over-year basis. As a group, equities research analysts anticipate that Intellia Therapeutics will post -5.21 EPS for the current year.
Insider Activity
In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.20% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Blue Trust Inc. increased its holdings in shares of Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after buying an additional 1,550 shares in the last quarter. Eastern Bank purchased a new position in Intellia Therapeutics in the third quarter valued at $41,000. First Horizon Advisors Inc. raised its position in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock worth $58,000 after acquiring an additional 472 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $54,000. 88.77% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
